### Analysis

Merck & Co., Inc.'s Q3 2017 earnings call highlighted strong operational performance, despite several challenges. Key points include:

1. **Financial Performance**: The company reported revenues of $10.3 billion, a decrease of 2% year over year, driven by the loss of exclusivity for several products. Non-GAAP EPS was $1.11, up 4% year over year.

2. **Product Performance**: KEYTRUDA remained a strong performer, with sales exceeding $1 billion for the first time. The company also saw growth in Animal Health and Vaccines businesses.

3. **Guidance**: The company narrowed and raised its revenue range for 2017 to $40 billion-$40.5 billion and expected non-GAAP EPS to be between $3.91 and $3.97.

4. **Outlook**: The company expects continued growth in KEYTRUDA, GARDASIL, and Animal Health. It also anticipates increased R&D expenses to support its pipeline.

### Short-Term Implications

1. **Stock Performance**: The stock is likely to face short-term pressure due to tempered guidance and the impact of the cyber incident.

2. **Investor Sentiment**: Investors may be cautious about the company's ability to maintain growth momentum in the face of challenges such as the loss of exclusivity on certain products and the impact of the cyber incident.

### Conclusion

The company's performance was mixed, with strong operational results but tempered by challenges. The stock is likely to face short-term pressure due to these factors.

**Rating: -1**